About orbsen

This author has not yet filled in any details.
So far orbsen has created 12 blog entries.
2 10, 2018

Orbsen Therapeutics’ NEPHSTROM Clinical Trial Underway at Four European Union Locations

2018-10-04T23:32:24+00:00 October 2nd, 2018|

Orbsen Therapeutics’ NEPHSTROM Clinical Trial Underway at Four European Union Locations Patients with diabetic kidney disease are being treated with a breakthrough stromal cell immunotherapy (October 2, 2018) Galway, Ireland — Orbsen Therapeutics, a biotechnology company focused on the discovery, development and commercialization of first-in-class stromal cell immunotherapies, announced that ORBCEL-M™, a second generation [...]

22 02, 2018

Irish Times Features

2018-03-06T20:17:18+00:00 February 22nd, 2018|

NUI Galway leads stem-cell research on diabetic kidney disease, €1.7m in funding for twenty new high-potential research projects announced, Scientific research projects get €1.7million funding boost, Orbsen Therapeutics to take part in €6m liver disease clinical trial, Innovation Awards profile: Orbsen Therapeutics – Stem cell research, The cream of start-ups, college spin-offs and smooth operators. […]

22 02, 2018

Dr. Larry Couture Named CEO Of Orbsen Therapeutics

2018-03-15T12:35:48+00:00 February 22nd, 2018|

NEW YORK, Sept. 6, 2016 /PRNewswire/ — Dr. Jack Kavanaugh, Chairman of Orbsen Therapeutics (http://www.orbsentherapeutics.com/), announced today the appointment of Larry Couture, PhD, as CEO. “Dr. Couture brings a remarkable background in cellular and genetic therapeutics with industry leading experience in both the scientific and business development of leading edge therapeutics,” said Kavanaugh. He added, “His industry experience at [...]

22 02, 2018

Orbsen Therapeutics Receives Approval from European Regulators for Clinical Trial of Breakthrough Cell Therapy for Diabetic Kidney Disease

2018-03-06T20:17:32+00:00 February 22nd, 2018|

NEW YORK–(BUSINESS WIRE)–Orbsen Therapeutics (www.orbsentherapeutics.com) breakthrough stromal cell immunotherapy, OBRCEL-M™, developed as part of NEPHSTROM, a European Union Horizon 2020-funded research project coordinated by NUI Galway, has been approved to begin testing in a randomised, double blind, and placebo-controlled European clinical trial to treat diabetic kidney disease. […]

25 04, 2016

Dr. Jack Kavanaugh Named Chairman of Orbsen

2018-03-15T12:35:48+00:00 April 25th, 2016|

Dr. Jack Kavanaugh, an internationally recognized surgeon and businessman who has spearheaded the commercialization of cellular therapies and emerging biotechnology firms has been named Chairman of Orbsen Therapeutics, it was announced today by Dr. Chris Coughlan, Founding Director. “Orbsen Therapeutics has developed cutting edge stem cell technology and is poised to become a leader in [...]

1 12, 2015

Orbsen Awarded 6 Million Euros to Test Cell Therapy for Diabetic Kidney Disease

2018-03-15T12:35:48+00:00 December 1st, 2015|

8 June 2015: TheJournal.ie: “NUI Galway spin-out company Orbsen Therapeutics used patented technology to discover the stromal cell therapy, which uses cells purified from healthy donor bone marrow. The four-year research project will see some 48 patients taking part in clinical trials in Galway, Belfast, Birmingham and Bergamo to test the treatment.” […]

1 12, 2015

NUI Galway Leads Stem Cell Research on Diabetic Kidney Disease

2015-12-13T07:06:37+00:00 December 1st, 2015|

 8 June, 2015:  The Irish Times covered the kick-off of Nephstrom. "The new €6 million EU-funded project, led by NUIG Regenerative Medicine Institute director Prof Timothy O’Brien, will evaluate a type of “next-generation” cell therapy discovered by researchers at the NUIG campus company Orbsen Therapeutics." Read the complete story at the Irish Times, or learn [...]

18 11, 2015

ORBCEL-M and Nephstrom In the Spotlight

2015-12-01T10:45:28+00:00 November 18th, 2015|

The Nephstrom project and the promise of Orbsen’s stromal cell therapy are up for discussion when RegMedNet interviews Remedi Chair (and Orbsen Director), Professor Timothy O’Brien. “Funded by a €6-million grant from the European Union Horizon 2020 programme and including many partners, the project is now setting up a stem cell factory with the NHS [...]

18 11, 2015

A Day in the Life of Orbsen’s Dr Steve Elliman

2018-03-15T12:35:48+00:00 November 18th, 2015|

Smartfutures interviews Dr. Steve Elliman, head of research at Orbsen Therapeutics, who says no two days are the same at his Galway start-up. Describe your typical day My chief function is to manage 11 research scientists in the lab. Another role is grant writing. We’re a start-up so we don’t [...]